Skip to content

LuncoLive Project

The LuncoLive project is funded by the European Innovation Council under the number 190172852

Project Objectives

Orixha offers a major clinical breakthrough in Critical Care with its unique LUNg COnservative LIquid VEntilation (hence LunCoLive) technology. It powers the Vent2Cool medical device to induce ultra-rapid protective cooling of heart and brain of resuscitated cardiac arrest patients. Vent2Cool will increase their survival rate by tackling the reperfusion injury of Post Cardiac Arrest Syndrome.

LuncoLive project will enable clinical validation of Vent2Cool as a new gold standard for post-resuscitation care. Orixha will industrialize and miniaturize the technology to increase usability as well as reduce costs and environmental impact, in particular through recycling of the Liquid2Breathe breathable liquid.

The goal of the LuncoLive Project is to obtain CE Mark of the Vent2Cool device in 2027 and subsequent commercial launch in the EU.  Once validated clinically and adopted in most cardiac arrest centers, Vent2Cool holds the potential to save 10,000 cardiac arrest patients / year in Europe by the end of the decade.

lign

Achievements of LunCoLive project

To date, the Orixha’s team and its partners have enabled the LuncoLive project to reach the following milestones:

  • Development and pre-clinical validation of Vent2Cool system, which includes an improved liquid ventilator and breathable circuit.
  • Identification of the process at pilot and industrial scale for recycling the Liquid2Breathe breathable liquid.
  • Obtention of biocompatibility status on Liquid2Breathe and the Breathable Circuit.
  • Set up and filing of the Vent2Cool technical file to the French authorities for the OverCool first in human feasibility clinical trial.
  • Obtention of the French Health Authority approval to initiate its feasibility clinical study in Post Cardiac Arrest Syndrome
  • Enrollment of the first patient in the OverCool trial in 2025.

Another major event was the 4 M€ pre-Series A fund raising led by the EIC Fund and BPI France which strengthens the balance sheet and the governance or the company.

lign2

Next steps

The OverCool study is expected to be completed by end of 2027 thanks to the involvement of the nurse and intensivist teams at Hôpital Cochin Paris and CHU Angers Hospital.

The clinical results shall pave the way for a CE Mark of Vent2Cool in 2029. CE mark approval will enable Orixha and its partners to launch this unique life-saving sloution for resuscitated cardiac arrest patients in Intensive Care Units across Europe from 2030.